The relationship of vascular changes to metabolic factor role in the development of peripheral nerve complication

Diabetes/metabolism Reviews 10, 189-224 DOI: 10.1002/dmr.5610100302

Citation Report

#	Article	IF	CITATIONS
1	Reversal of peripheral nerve conduction and perfusion deficits by the free radical scavenger, BM15.0639, in diabetic rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 1995, 352, 685-90.	1.4	20
2	Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant ?-lipoic acid. Diabetologia, 1995, 38, 1425-1433.	2.9	490
3	Chronic vitamin E treatment prevents defective endothelium-dependent relaxation in diabetic rat aorta. Diabetologia, 1995, 38, 1475-1478.	2.9	133
4	Effects of natural free radical scavengers on peripheral nerve and neurovascular function in diabetic rats. Diabetologia, 1995, 38, 1285-1294.	2.9	121
5	Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes/metabolism Reviews, 1995, 11, 193-225.	0.2	147
6	Neuroprotective effects of carvedilol in diabetic rats: prevention of defective peripheral nerve perfusion and conduction velocity. Naunyn-Schmiedeberg's Archives of Pharmacology, 1995, 351, 630-5.	1.4	17
7	Impaired myelinated fiber regeneration following freeze-injury in rats with streptozotocin-induced diabetes: involvement of the polyol pathway. Brain Research, 1995, 703, 105-110.	1.1	16
8	Nerve function and regeneration in diabetic rats: effects of ZD-7155, an AT1 receptor antagonist. American Journal of Physiology - Endocrinology and Metabolism, 1995, 269, E530-E537.	1.8	20
9	New approaches for treatment in diabetes: Aldose reductase inhibitors. Biomedicine and Pharmacotherapy, 1995, 49, 232-243.	2.5	55
10	Nerve function in galactosaemic rats: effects of evening primrose oil and doxazosin. European Journal of Pharmacology, 1995, 281, 303-309.	1.7	5
11	Polyol pathway, 2,3-diphosphoglycerate in erythrocytes and diabetic neuropathy in rats. European Journal of Pharmacology, 1995, 294, 207-214.	1.7	18
12	Gosha-jinki-gan (herbal medicine) in streptozocin-induced diabetic neuropathy. Journal of the Neurological Sciences, 1995, 132, 177-181.	0.3	37
13	Natural History of Peripheral Neuropathy in Patients with Non-Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine, 1995, 333, 89-94.	13.9	561
14	DIABETES AND THE NERVOUS SYSTEM. Endocrinology and Metabolism Clinics of North America, 1996, 25, 325-359.	1.2	59
15	Failure of nimodipine to prevent or correct the long-term nerve conduction defect and increased neuronal Ca2+-currents in the diabetic BB/W-rat. Diabetes Research and Clinical Practice, 1996, 32, 135-140.	1.1	9
16	The calcium hypothesis of brain aging and neurodegenerative disorders: Significance in diabetic neuropathy. Life Sciences, 1996, 59, 379-387.	2.0	60
17	Presynaptic deficit of sympathetic nerves: a cause for disturbed sciatic nerve blood flow responsiveness in diabetic rats. European Journal of Pharmacology, 1996, 296, 277-283.	1.7	10
18	Rapid reversal by aminoguanidine of the neurovascular effects of diabetes in rats: Modulation by nitric oxide synthase inhibition. Metabolism: Clinical and Experimental, 1996, 45, 1147-1152.	1.5	43

#	Article	IF	CITATIONS
19	Nerve function and regeneration in diabetic and galactosaemic rats: antioxidant and metal chelator effects. European Journal of Pharmacology, 1996, 314, 33-39.	1.7	28
20	Effectiveness of natural oils as sources of γ-linolenic acid to correct peripheral nerve conduction velocity abnormalities in diabetic rats: modulation by thromboxane A2 inhibition. Prostaglandins Leukotrienes and Essential Fatty Acids, 1996, 55, 159-165.	1.0	21
21	Effects of propionyl-l-carnitine and insulin on the electroretinogram, nerve conduction and nerve blood flow in rats with streptozotocin-induced diabetes. Pflugers Archiv European Journal of Physiology, 1996, 431, 564-570.	1.3	9
22	Interaction between oxidative stress and gamma-linolenic acid in impaired neurovascular function of diabetic rats. American Journal of Physiology - Endocrinology and Metabolism, 1996, 271, E471-E476.	1.8	15
23	Oxidative Stress and Lipids in Diabetes: A Role in Endothelium Vasodilator Dysfunction?. Vascular Medicine, 1996, 1, 195-206.	0.8	65
24	Antioxidants in peripheral nerve. Free Radical Biology and Medicine, 1996, 20, 925-932.	1.3	29
25	Nerve fiber regeneration following axotomy in the diabetic biobreeding Worcester rat: The effect of ARI treatment. Journal of Diabetes and Its Complications, 1996, 10, 183-191.	1.2	37
26	Effects of α-tocopherol on nerve conduction velocity and regeneration following a freeze lesion in immature diabetic rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 355, 126-130.	1.4	11
27	Comparison of the effects of ascorbyl ?-linolenic acid and ?-linolenic acid in the correction of neurovascular deficits in diabetic rats. Diabetologia, 1996, 39, 1047-1054.	2.9	44
28	Impairment of afferent arteriolar myogenic responsiveness in the galactose-fed rat is prevented by tolrestat. Diabetologia, 1996, 39, 907-914.	2.9	14
29	Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats. Diabetologia, 1996, 39, 172-182.	2.9	97
30	Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia, 1996, 39, 329-335.	2.9	185
31	Contraction and relaxation of aortas from diabetic rats: effects of chronic anti-oxidant and aminoguanidine treatments. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 353, 584-91.	1.4	47
32	Effects of the sulphydryl donor N-acetyl-L-cysteine on nerve conduction, perfusion, maturation and regeneration following freeze damage in diabetic rats. European Journal of Clinical Investigation, 1996, 26, 698-706.	1.7	43
33	The Efficacy of Tolrestat in the Treatment of Diabetic Peripheral Neuropathy: A meta-analysis of individual patient data. Diabetes Care, 1996, 19, 1091-1096.	4.3	27
34	Role of polyol pathway in nonenzymatic glycation. Nephrology Dialysis Transplantation, 1996, 11, 95-98.	0.4	50
35	Place Learning and Hippocampal Synaptic Plasticity in Streptozotocin-Induced Diabetic Rats. Diabetes, 1996, 45, 1259-1266.	0.3	361
36	Effects of adrenergic stimulation on sciatic nerve blood flow in diabetic and control rats. European Journal of Pharmacology, 1997, 329, 147-152.	1.7	4

#	Article	IF	CITATIONS
37	Diabetic neuropathy in sucrose-fed otsuka long-evans tokushima fatty rats: Effect of an aldose reductase inhibitor, TAT. Life Sciences, 1997, 60, 1847-1857.	2.0	23
38	Effects of dietary supplementation with arachidonic acid rich oils on nerve conduction and blood flow in streptozotocin-diabetic rats. Prostaglandins Leukotrienes and Essential Fatty Acids, 1997, 56, 337-343.	1.0	23
39	Neurovascular effects of l-carnitine treatment in diabetic rats. European Journal of Pharmacology, 1997, 319, 239-244.	1.7	14
40	Effects of diabetes on reactivity of sciatic vasa nervorum in rats. Journal of Diabetes and Its Complications, 1997, 11, 47-55.	1.2	47
41	The level of erythrocyte aldose reductase: a risk factor for diabetic neuropathy?. Diabetes Research and Clinical Practice, 1997, 36, 161-167.	1.1	26
42	The level of erythrocyte aldose reductase is associated with the severity of diabetic retinopathy. Diabetes Research and Clinical Practice, 1997, 37, 173-177.	1.1	22
43	Increased sciatic nerve blood flow in diabetic rats: assessment by "molecular" vs. particulate microspheres. American Journal of Physiology - Endocrinology and Metabolism, 1997, 273, E164-E173.	1.8	11
44	Diabetes impairs sciatic nerve hyperemia induced by surgical trauma: implications for diabetic neuropathy. American Journal of Physiology - Endocrinology and Metabolism, 1997, 273, E174-E184.	1.8	8
46	Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia, 1997, 40, 271-281.	2.9	146
47	Effect of the Aldose Reductase Inhibitor Tolrestat on Nerve Conduction Velocity, NA/K ATPase Activity, and Polyols in Red Blood Cells, Sciatic Nerve, Kidney Cortex, and Kidney Medulla of Diabetic Rats. Journal of Diabetes and Its Complications, 1998, 12, 154-162.	1.2	44
48	Effect of Aldose Reductase Inhibition on Cardiovascular Reflex Tests in Patients with Definite Diabetic Autonomic Neuropathy Over a Period of 2 Years. Journal of Diabetes and Its Complications, 1998, 12, 201-207.	1.2	13
49	Flow-induced dilatation in isolated resistance arteries from control and streptozotocin-diabetic rats. Diabetologia, 1998, 41, 34-39.	2.9	37
50	Effects of α-lipoic acid on neurovascular function in diabetic rats: interaction with essential fatty acids. Diabetologia, 1998, 41, 390-399.	2.9	146
51	Amelioration of neurovascular deficits in diabetic rats by a novel aldose reductase inhibitor, GP-1447: Minor contribution of nitric oxide. Diabetes Research and Clinical Practice, 1998, 40, 101-112.	1.1	6
52	Erythrocyte aldose reductase protein: a clue to elucidate risk factors for diabetic neuropathies independent of glycemic control. Diabetes Research and Clinical Practice, 1998, 42, 101-107.	1.1	9
53	Evening primrose oil treatment corrects reduced conduction velocity but not depletion of arachidonic acid in nerve from streptozotocin-induced diabetic rats. Prostaglandins Leukotrienes and Essential Fatty Acids, 1998, 59, 195-202.	1.0	8
54	Effects of the peptide HP228 on nerve disorders in diabetic rats. Metabolism: Clinical and Experimental, 1998, 47, 650-656.	1.5	18
55	PERIPHERAL NEUROPATHIES IN DIABETES. Surgical Clinics of North America, 1998, 78, 393-408.	0.5	18

	Ci	tation Report	
#	Article	IF	CITATIONS
56	Nerve Growth Factor (NGF) and Diabetic Neuropathy in the Rat: Morphological Investigations of the Sural Nerve, Dorsal Root Ganglion, and Spinal Cord. Experimental Neurology, 1998, 153, 23-34.	2.0	68
57	Correction of neurovascular deficits in diabetic rats by β2-adrenoceptor agonist and α1-adrenocepto antagonist treatment: Interactions with the nitric oxide system. European Journal of Pharmacology, 1998, 343, 217-223.	r 1.7	26
58	Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associate with a polymorphism at the 5' end of the aldose reductase gene. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 64, 213-216.	d 0.9	68
59	Diabetes and wound healing. Journal of Wound Care, 1998, 7, 47-51.	0.5	58
60	Neurophysiological changes in the central and peripheral nervous system of streptozotocin-diabetic rats. Brain, 1999, 122, 757-768.	3.7	126
61	Disturbed microvascular reactivity and shunting - a major cause for diabetic complications. Vascular Medicine, 1999, 4, 125-127.	0.8	40
62	Prevalence of autoantibodies to autonomic nervous tissue structures in Type 1 diabetes mellitus. Diabetic Medicine, 1999, 16, 544-549.	1.2	27
63	Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabetic Medicine, 1999, 16, 1040-1043.	1.2	162
64	Hyperhomocysteinaemia is not related to risk of distal somatic polyneuropathy: The Hoorn Study. Journal of Internal Medicine, 1999, 246, 561-566.	2.7	16
65	Experimental diabetic neuropathy: an update. Diabetologia, 1999, 42, 773-788.	2.9	228
66	A new minimally invasive technique to show nerve ischaemia in diabetic neuropathy. Diabetologia, 1999, 42, 737-742.	2.9	55
67	Only limited effects of aminoguanidine treatment on peripheral nerve function, (Na + ,K +)-ATPase activity and thrombomodulin expression in streptozotocin-induced diabetic rats. Diabetologia, 1999, 42, 743-747.	2.9	23
68	Effects of chelator treatment on aorta and corpus cavernosum from diabetic rats. Free Radical Biology and Medicine, 1999, 27, 536-543.	1.3	38
69	Effects of the Diacylglycerol Complexing Agent, Cremophor, on Nerve-Conduction Velocity and Perfusion in Diabetic Rats. Journal of Diabetes and Its Complications, 1999, 13, 2-9.	1.2	21
70	Diabetes does not alter the activity and localisation of nitric oxide synthase in the rat anococcygeus muscle. Journal of the Autonomic Nervous System, 1999, 76, 35-44.	1.9	10
71	Cerebral complications of diabetes: clinical findings and pathogenetic mechanisms. Netherlands Journal of Medicine, 1999, 54, 35-45.	0.6	62
72	Beneficial effect of thyrotropin-releasing hormone on neuropathy in diabetic rats. Diabetes Research and Clinical Practice, 1999, 44, 93-100.	1.1	2
73	Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes. Diabetes Researcl and Clinical Practice, 1999, 45, 137-146.	n 1.1	147

#	Article	IF	CITATIONS
74	Nerve conduction and antioxidant levels in experimentally diabetic rats: Effects of streptozotocin dose and diabetes duration. Metabolism: Clinical and Experimental, 1999, 48, 442-447.	1.5	34
75	Total homocysteine is associated with nephropathy in non—insulin-dependent diabetes mellitus. Metabolism: Clinical and Experimental, 1999, 48, 1096-1101.	1.5	71
76	Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (α-lipoic acid): A two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research, 1999, 31, 171-179.	1.5	251
77	Diabetes and peripheral vascular disease. Journal of Vascular Surgery, 1999, 30, 373-384.	0.6	123
78	Effects of hindlimb temperature on sciatic nerve laser Doppler vascular conductance in control and streptozotocin-diabetic rats. Journal of the Neurological Sciences, 1999, 163, 17-24.	0.3	10
79	The Effect of α-Lipoic Acid on the Neurovascular Reflex Arc in Patients with Diabetic Neuropathy Assessed by Capillary Microscopy. Microvascular Research, 1999, 58, 28-34.	1.1	41
80	Impaired regeneration and no amelioration with aldose reductase inhibitor in crushed unmyelinated nerve fibers of diabetic rats. NeuroReport, 1999, 10, 2405-2409.	0.6	13
81	ATP-sensitive K+ channel effects on nerve function, Na+, K+ ATPase, and glutathione in diabetic rats. European Journal of Pharmacology, 2000, 397, 335-341.	1.7	30
82	A comparison of diabetic polyneuropathy in Type II diabetic BBZDR/Wor rats and in Type I diabetic BB/Wor rats. Diabetologia, 2000, 43, 786-793.	2.9	118
83	Pentoxifylline Effects on Nerve Conduction Velocity and Blood Flow in Diabetic Rats. International Journal of Experimental Diabetes Research, 2000, 1, 49-58.	1.0	11
84	Neurological Recovery From Closed Head Injury is Impaired in Diabetic Rats. Journal of Neurotrauma, 2000, 17, 1013-1027.	1.7	18
85	Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm. Cardiovascular Research, 2000, 47, 475-488.	1.8	142
86	Lower Extremity Revascularization in Diabetes. Archives of Surgery, 2000, 135, 452.	2.3	102
87	Autonomic dysfunction is related to impaired pancreatic beta cell function in patients with coronary artery disease. British Heart Journal, 2000, 83, 210-216.	2.2	11
88	Cognition and synaptic plasticity in diabetes mellitus. Trends in Neurosciences, 2000, 23, 542-549.	4.2	671
89	The effect of gamma-linolenic acid–alpha-lipoic acid on functional deficits in the peripheral and central nervous system of streptozotocin-diabetic rats. Journal of the Neurological Sciences, 2001, 182, 99-106.	0.3	37
90	Ozone treatment reduces markers of oxidative and endothelial damage in an experimental diabetes model in rats. Pharmacological Research, 2001, 44, 391-396.	3.1	74
91	Effect of zenarestat, an aldose reductase inhibitor, on endoneurial blood flow in experimental diabetic neuropathy of rat. Neuroscience Letters, 2001, 310, 81-84.	1.0	18

#	Article	IF	CITATIONS
92	Physiological and morphometric analyses of neuropathy in sucrose-fed OLETF rats. Diabetes Research and Clinical Practice, 2001, 51, 9-20.	1.1	25
93	Effect of Dietary Vitamin E Supplementationon Vascular Reactivity of Thoracic Aorta in Streptozotocin-Diabetic Rats. Pharmacology, 2001, 62, 56-64.	0.9	49
94	Diagnosis and treatment of diabetic autonomic neuropathy. Current Diabetes Reports, 2001, 1, 216-227.	1.7	39
95	Glutathione and α-lipoate in diabetic rats: nerve function, blood flow and oxidative state. European Journal of Clinical Investigation, 2001, 31, 417-424.	1.7	34
96	Relation between homocysteinaemia and diabetic neuropathy in patients with Type 2 diabetes mellitus. Diabetic Medicine, 2001, 18, 185-192.	1.2	77
97	Corpus cavernosum dysfunction in diabetic rats: effects of combined ?-lipoic acid and ?-linolenic acid treatment. Diabetes/Metabolism Research and Reviews, 2001, 17, 380-386.	1.7	33
98	Effect of α-lipoic acid on vascular responses and nociception in diabetic rats. Free Radical Biology and Medicine, 2001, 31, 125-135.	1.3	87
99	Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain, 2001, 124, 2448-2458.	3.7	145
100	Microvascular disease aetiology in diabetic foot ulceration. Journal of Wound Care, 2001, 10, 159-162.	0.5	2
101	Therapeutic potential of PKC inhibitors in painful diabetic neuropathy. Expert Opinion on Investigational Drugs, 2001, 10, 1653-1664.	1.9	36
102	Dissection of Metabolic, Vascular, and Nerve Conduction Interrelationships in Experimental Diabetic Neuropathy by Cyclooxygenase Inhibition and Acetyl-L-Carnitine Administration. Diabetes, 2002, 51, 2619-2628.	0.3	92
103	Protein kinase C changes in diabetes: Is the concept relevant to neuropathy?. International Review of Neurobiology, 2002, 50, 61-82.	0.9	62
104	Effect of treatment of diabetic rats with dehydroepiandrosterone on vascular and neural function. American Journal of Physiology - Endocrinology and Metabolism, 2002, 283, E1067-E1075.	1.8	70
105	The Effects of a Traditional Medicine, Fang-ji-huang-qi-tang (Boi-ogi-to), on Urinary Sugar and Sugar Alcohols in Streptozotocin-induced Diabetic Mice Journal of Health Science, 2002, 48, 168-172.	0.9	2
106	Effects of Trientine, a Metal Chelator, on Defective Endothelium-dependent Relaxation in the Mesenteric Vasculature of Diabetic Rats. Free Radical Research, 2002, 36, 1091-1099.	1.5	24
107	Haemodynamics in microvascular complications in type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2002, 18, 286-304.	1.7	34
108	Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney International, 2002, 61, 939-950.	2.6	338
109	Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods for Human Nutrition, 2002, 57, 41-52.	1.4	288

#	Article	IF	CITATIONS
110	The effects of 5-hydroxytryptamine 5-HT2 receptor antagonists on nerve conduction velocity and endoneurial perfusion in diabetic rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2003, 367, 607-614.	1.4	10
111	Overview of the diabetic foot. Seminars in Vascular Surgery, 2003, 16, 3-11.	1.1	27
112	Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity and cerebral blood flow in streptozotocin-diabetic rats. Brain Research, 2003, 966, 274-282.	1.1	73
113	Impaired 0.1-Hz vasomotion assessed by laser Doppler anemometry as an early index of peripheral sympathetic neuropathy in diabetes. Microvascular Research, 2003, 65, 88-95.	1.1	57
114	Diabetic neuropathy and nerve regeneration. Progress in Neurobiology, 2003, 69, 229-285.	2.8	221
115	Looking to the future: diabetic neuropathy and effects of rosuvastatin on neurovascular function in diabetes models. Diabetes Research and Clinical Practice, 2003, 61, S35-S39.	1.1	50
117	Preventing Superoxide Formation in Epineurial Arterioles of the Sciatic Nerve from Diabetic Rats Restores Endothelium-dependent Vasodilation. Free Radical Research, 2003, 37, 33-40.	1.5	74
118	Effect of Various Nerve Decompression Procedures on the Functions of Distal Limbs in Streptozotocin-Induced Diabetic Rats: Further Optimism in Diabetic Neuropathy. Plastic and Reconstructive Surgery, 2003, 111, 2265-2272.	0.7	46
119	Effect of an aqueous extract of Scoparia dulcis on blood glucose, plasma insulin and some polyol pathway enzymes in experimental rat diabetes. Brazilian Journal of Medical and Biological Research, 2004, 37, 577-586.	0.7	83
120	Sonic Hedgehog Induces Arteriogenesis in Diabetic Vasa Nervorum and Restores Function in Diabetic Neuropathy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 2102-2107.	1.1	106
121	Auditory brainstem evoked responses in insulin-dependent (ID) and non-insulin-dependent (NID) diabetic subjects with normal hearing. International Journal of Audiology, 2004, 43, 29-33.	0.9	42
122	Differences between collagen morphologies, properties and distribution in diabetic and normal biobreeding and Sprague–Dawley rat sciatic nerves. Journal of Biomechanics, 2004, 37, 879-888.	0.9	27
124	Distal Sensorimotor Polyneuropathy Affects Skeletal Muscle Perfusion and Metabolism by Tc-99m Sestamibi Leg Scintigraphy in Patients With Type 2 Diabetes. , 2005, 15, 146-149.		1
125	Therapeutic efficacy of ozone in patients with diabetic foot. European Journal of Pharmacology, 2005, 523, 151-161.	1.7	188
126	Disorders of Transmission via a Peripheral Nerve Related to Experimental Diabetic Peripheral Neuropathy in Rats: Possibilities for Pharmacological Correction. Neurophysiology, 2005, 37, 67-72.	0.2	0
127	The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy. Journal of the Neurological Sciences, 2006, 247, 217-223.	0.3	61
128	The Effect of Nimodipine on Calcium Homeostasis and Pain Sensitivity in Diabetic Rats. Cellular and Molecular Neurobiology, 2006, 26, 1539-1555.	1.7	20
129	Effect of the aldose reductase inhibitor fidarestat on experimental diabetic neuropathy in the rat. Diabetologia, 2006, 49, 3085-3093.	2.9	30

#	Article	IF	CITATIONS
130	Current Concepts in Diabetic Microvascular Dysfunction. Journal of the American Podiatric Medical Association, 2006, 96, 245-252.	0.2	20
131	Towards Newer Molecular Targets for Chronic Diabetic Complications. Current Vascular Pharmacology, 2006, 4, 45-57.	0.8	52
132	Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: A multimodal analysis. Neuroscience, 2007, 144, 1293-1304.	1.1	175
133	Contrast-enhanced imaging of cerebral vasculature with laser speckle. Applied Optics, 2007, 46, 5340.	2.1	64
134	Acetyl-L-Carnitine in Diabetic Polyneuropathy. CNS Drugs, 2007, 21, 13-23.	2.7	31
135	The Association of Aldose Reductase Gene Polymorphisms with Neuropathy in Patients with Type 2 Diabetes. The Journal of Korean Diabetes Association, 2007, 31, 274.	0.1	1
136	Polyneuropathies. , 2007, , 514-537.		0
137	Diabetic neuropathy: Mechanisms to management. , 2008, 120, 1-34.		588
138	Endoneurial microvascular pathology in feline diabetic neuropathy. Microvascular Research, 2008, 75, 403-410.	1.1	46
139	Protective and therapeutic effects of swimming exercise training on diabetic peripheral neuropathy of streptozotocin-induced diabetic rats. Journal of Endocrinological Investigation, 2008, 31, 971-978.	1.8	31
140	High resolution mapping of cortical blood flow by mosaicing the laser speckle images. , 2008, 2008, 3743-6.		0
141	Impaired microvascular perfusion: a consequence of vascular dysfunction and a potential cause of insulin resistance in muscle. American Journal of Physiology - Endocrinology and Metabolism, 2008, 295, E732-E750.	1.8	157
142	Bone Marrow Mononuclear Cells Have Neurovascular Tropism and Improve Diabetic Neuropathy. Stem Cells, 2009, 27, 1686-1696.	1.4	58
143	Diabetic Critical Ischemia of Lower Limbs: Distal Arterial Revascularisation. Acta Chirurgica Belgica, 2009, 109, 321-326.	0.2	4
144	Glutamate Carboxypeptidase Inhibition Reduces the Severity of Chemotherapy-Induced Peripheral Neurotoxicity in Rat. Neurotoxicity Research, 2010, 17, 380-391.	1.3	59
145	Diabetes and chronic oxidative stress. A perspective based on the possible usefulness of ozone therapy. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2011, 5, 45-49.	1.8	35
146	Altered nerve excitability in subclinical/early diabetic neuropathy: Evidence for early neurovascular process in diabetes mellitus?. Diabetes Research and Clinical Practice, 2011, 91, 183-189.	1.1	25
147	Simultaneous automatic arteries-veins separation and cerebral blood flow imaging with single-wavelength laser speckle imaging. Optics Express, 2011, 19, 15777.	1.7	17

#	Article	IF	CITATIONS
148	Cell Therapy for Diabetic Neuropathy. , 0, , .		0
149	REMEDIAL EFFECTS OF VITAMIN E AND L-ARGININE ON PERIPHERAL NEUROPATHY IN STREPTOZOTOCIN-INDUCED DIABETIC RATS. American Journal of Pharmacology and Toxicology, 2014, 9, 13-23.	0.7	2
150	Effect of Whole Body Vibration on Skin Blood Flow and Nitric Oxide Production. Journal of Diabetes Science and Technology, 2014, 8, 889-894.	1.3	44
151	Pathogenesis of Chronic Hyperglycemia: From Reductive Stress to Oxidative Stress. Journal of Diabetes Research, 2014, 2014, 1-11.	1.0	261
152	Histopathologic Changes in the Cochlea Associated With Diabetes Mellitus—A Review. Otology and Neurotology, 2014, 35, 764-774.	0.7	46
153	The comparison of muscle strength and short-term endurance in the different periods of type 2 diabetes. Journal of Diabetes and Metabolic Disorders, 2014, 13, 22.	0.8	25
154	Hematocrit dispersion in asymmetrically bifurcating vascular networks. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H1576-H1586.	1.5	21
156	An integrated medical treatment for type-2 diabetes. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2014, 8, 57-61.	1.8	17
157	Characterization of nerve and microvessel damage and recovery in type 1 diabetic mice after permanent femoral artery ligation. Journal of Neuroscience Research, 2015, 93, 1451-1461.	1.3	4
158	Vascular Impairment of Epineurial Arterioles of the Sciatic Nerve: Implications for Diabetic Peripheral Neuropathy. Review of Diabetic Studies, 2015, 12, 13-28.	0.5	24
159	Isokinetic and Electromyographic Properties of Muscular Endurance in Short and Long-Term Type 2 Diabetes. Global Journal of Health Science, 2015, 8, 210.	0.1	6
160	Accessing to arteriovenous blood flow dynamics response using combined laser speckle contrast imaging and skin optical clearing. Biomedical Optics Express, 2015, 6, 1977.	1.5	53
161	The Protective Effect of Antioxidants Consumption on Diabetes and Vascular Complications. Diseases (Basel, Switzerland), 2016, 4, 24.	1.0	60
162	Effects of S-Allylcysteine on Biomarkers of the Polyol Pathway in Rats with Type 2 Diabetes. Canadian Journal of Diabetes, 2016, 40, 442-448.	0.4	26
163	Detrended fluctuation analysis of compound action potentials re-corded in the cutaneous nerves of diabetic rats. Chaos, Solitons and Fractals, 2016, 83, 223-233.	2.5	2
164	Blockade of sigma 1 receptors alleviates sensory signs of diabetic neuropathy in rats. European Journal of Pain, 2017, 21, 61-72.	1.4	21
165	Antioxidant Effects of Biochanin A in Streptozotocin Induced Diabetic Rats. Brazilian Archives of Biology and Technology, 2017, 60, .	0.5	33
166	Therapeutic relevance of ozone therapy in degenerative diseases: Focus on diabetes and spinal pain. Journal of Cellular Physiology, 2018, 233, 2705-2714.	2.0	59

#	Article	IF	CITATIONS
167	Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets. European Journal of Pharmacology, 2018, 833, 472-523.	1.7	190
168	Gene therapy with the angiogenic neuropeptide secretoneurin ameliorates experimental diabetic neuropathy. FASEB Journal, 2018, 32, 4815-4823.	0.2	6
169	Efficacy of a Methanolic Extract of Adansonia digitata Leaf in Alleviating Hyperglycemia, Hyperlipidemia, and Oxidative Stress of Diabetic Rats. BioMed Research International, 2019, 2019, 1-10.	0.9	25
170	Sonographic assessment of nerve blood flow in diabetic neuropathy. Diabetic Medicine, 2020, 37, 343-349.	1.2	10
171	Emerging Roles of microRNAs as Biomarkers and Therapeutic Targets for Diabetic Neuropathy. Frontiers in Neurology, 2020, 11, 558758.	1.1	21
172	Soluble Epoxide Hydrolase Regulation of Lipid Mediators Limits Pain. Neurotherapeutics, 2020, 17, 900-916.	2.1	20
173	Folic acid and melatonin mitigate diabetic nephropathy in rats via inhibition of oxidative stress. Nutrition and Metabolism, 2020, 17, 6.	1.3	42
174	Differences and Similarities in Neuropathy in Type 1 and 2 Diabetes: A Systematic Review. Journal of Personalized Medicine, 2021, 11, 230.	1.1	16
175	Pharmacological Treatment of Painful Diabetic Neuropathy. , 1998, , 147-169.		2
176	The Impact of Micro-and Macrovascular Disease on Diabetic Neuropathy and Foot Problems. , 1998, , 319-331.		3
177	Histologic Changes. , 1998, , 77-87.		1
178	Painful Diabetic Neuropathy. , 1998, , 133-146.		2
180	Effects of natural free radical scavengers on peripheral nerve and neurovascular function in diabetic rats. Diabetologia, 1995, 38, 1285-1294.	2.9	13
181	Impairment of afferent arteriolar myogenic responsiveness in the galactose-fed rat is prevented by tolrestat. Diabetologia, 1996, 39, 907-914.	2.9	2
182	Comparison of the effects of ascorbyl g-linolenic acid and g-linolenic acid in the correction of neurovascular deficits in diabetic rats. Diabetologia, 1996, 39, 1047-1054.	2.9	3
183	Effects of propionyl- L -carnitine and insulin on the electroretinogram, nerve conduction and nerve blood flow in rats with streptozotocin-induced diabetes. Pflugers Archiv European Journal of Physiology, 1996, 431, 564-570.	1.3	2
184	Diabetic Neuropathy Modulation by Zinc and/or Polyphenol Administration. , 2017, , 87-100.		1
185	Effects of Aldose Reductase Inhibition on Responses of the Corpus Cavernosum and Mesenteric Vascular Bed of Diabetic Rats, Journal of Cardiovascular Pharmacology, 2000, 35, 606-613	0.8	41

#	Article	IF	CITATIONS
186	Visualization of skin microvascular dysfunction of type 1 diabetic mice using in vivo skin optical clearing method. Journal of Biomedical Optics, 2018, 24, 1.	1.4	16
187	Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents Journal of Clinical Investigation, 1995, 96, 1159-1163.	3.9	139
188	Primary preventive and secondary interventionary effects of acetyl-L-carnitine on diabetic neuropathy in the bio-breeding Worcester rat Journal of Clinical Investigation, 1996, 97, 1900-1907.	3.9	83
189	Reversal of experimental diabetic neuropathy by VEGF gene transfer. Journal of Clinical Investigation, 2001, 107, 1083-1092.	3.9	271
190	Lipoic Acid. , 2001, , .		1
191	Evolving Insights into the Pathophysiology of Diabetic Neuropathy: Implications of Malfunctioning Glia and Discovery of Novel Therapeutic Targets. Current Pharmaceutical Design, 2016, 22, 738-757.	0.9	23
192	Painful diabetic neuropathy: an update. Annals of Neurosciences, 2011, 18, 168-75.	0.9	41
193	Nitric Oxide, Peripheral Neuropathy, and Diabetes. , 2000, , 307-326.		1
195	Aminoguanidine Prevents the Depletion of Neurons Containing Nitric Oxide Synthase in the Streptozotocin Diabetic Rat. , 2005, , 279-284.		0
196	The Effect of Alpha-Lipoic Acid on the Protection of Epidermal Nerve Fibers and Microcapillaries in the Streptozotocin-Induced Diabetic Rats. The Journal of Korean Diabetes Association, 2007, 31, 488.	0.1	0
197	Mini-Review: The Influence of Respiratory and pH Imbalance in Cancer Development. International Journal of Biochemistry Research & Review, 2014, 4, 386-409.	0.1	2
198	Effect of Peaches, Pears and Green Tea on Plasma Lipids Profile and Antioxidant Content in Rats Fed High Sucrose Diet. Food and Nutrition Sciences (Print), 2015, 06, 893-905.	0.2	2
199	Protective Effect of Sweet Potato Peel against Oxidative Stress in Hyperlipidemic Albino Rats. Food and Nutrition Sciences (Print), 2019, 10, 503-516.	0.2	0
200	A Comprehensive Review of Neuronal Changes in Diabetics. Cureus, 2021, 13, e19142.	0.2	13
201	The Effect of Alpha-Lipoic Acid on the Protection of Epidermal Nerve Fibers and Microcapillaries in the Streptozotocin-Induced Diabetic Rats. The Journal of Korean Diabetes Association, 2007, 31, 488.	0.1	0